Marques Diogo Fp, Kovacs Dory, Sanchez-Ruiz Miguel-Angel, Rodrigues Ana Paula, Machado Ausenda, Mazagatos Clara, Monge Susana, Domegan Lisa, O'Donnell Joan, Hooiveld Mariette, Emborg Hanne-Dorthe, Nunes Baltazar, Carvalho Carlos, Rose Angela Mc
Epiconcept, Paris, France.
NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, NOVA University Lisbon, Lisbon, Portugal.
Euro Surveill. 2025 May;30(20). doi: 10.2807/1560-7917.ES.2025.30.20.2400655.
BackgroundBetween 2020 and 2023, ECDC has supported 21 of 30 EU/EEA and six Western Balkan countries by enhancing severe acute respiratory infection (SARI) surveillance to monitor trends, detect unexpected events, evaluate public health interventions, identify risk factors and support vaccine effectiveness studies. Using diverse strategies, countries have implemented SARI surveillance and reported data at national/European levels.AimWe evaluated European-level SARI surveillance and provided recommendations to achieve objectives and improve key attribute performance.MethodsWe analysed 2022/23 surveillance data for completeness. We administered a questionnaire, targeting country-level representatives, to evaluate surveillance attributes (meeting objectives, usefulness, acceptability, timeliness, representativeness) and identify strengths, weaknesses, opportunities and threats.ResultsThirteen countries (13/27) reported data at European level. Data showed good overall completeness but varied across countries and some variables need improvement (vaccination, sequencing). The questionnaire was completed by all 27 countries. Most countries (23/27) reported that the system effectively monitored trends and considered it useful and acceptable (25/27), but only 16 found it timely and 14 representative. Challenges included insufficient case-based data, data linkage issues and insufficient data completeness. Slow/inefficient manual data extraction affected timeliness, while insufficient geographical coverage affected representativeness. Multi-pathogen surveillance was identified as the main strength, heterogeneity of systems the main weakness, improvements of hospital information systems the main opportunity, and lack of sustainable funding the main threat.ConclusionsSARI surveillance was perceived as effective in monitoring trends, useful and acceptable. To achieve additional objectives and enhance timeliness and representativeness, we recommend improving data completeness, digitalisation/automation and geographical coverage.
背景
2020年至2023年期间,欧洲疾病预防控制中心(ECDC)通过加强严重急性呼吸道感染(SARI)监测,对30个欧盟/欧洲经济区国家中的21个以及6个西巴尔干国家提供了支持,以监测趋势、发现意外事件、评估公共卫生干预措施、识别风险因素并支持疫苗有效性研究。各国采用了多种策略实施SARI监测,并在国家/欧洲层面报告数据。
目的
我们评估了欧洲层面的SARI监测,并提出建议以实现目标并改善关键属性的表现。
方法
我们分析了2022/23年监测数据的完整性。我们向各国代表发放了一份问卷,以评估监测属性(实现目标情况、有用性、可接受性、及时性、代表性),并识别优势、劣势、机会和威胁。
结果
13个国家(13/27)在欧洲层面报告了数据。数据显示总体完整性良好,但各国情况不同,一些变量需要改进(疫苗接种、测序)。27个国家都完成了问卷。大多数国家(23/27)报告称该系统有效地监测了趋势,并认为其有用且可接受(25/27),但只有16个国家认为它及时,14个国家认为它具有代表性。挑战包括基于病例的数据不足、数据链接问题和数据完整性不足。缓慢/低效的手动数据提取影响了及时性,而地理覆盖范围不足影响了代表性。多病原体监测被认为是主要优势,系统的异质性是主要劣势,改善医院信息系统是主要机会,缺乏可持续资金是主要威胁。
结论
SARI监测被认为在监测趋势方面有效、有用且可接受。为了实现更多目标并提高及时性和代表性,我们建议提高数据完整性、数字化/自动化程度以及地理覆盖范围。